Glaxo’s Zofran
Executive Summary
Supplemental NDA for post-operative nausea and vomiting approved Aug. 13. Zofran (ondansetron), which is currently marketed for pervention of chemotherapy-induced nausea and vomiting, has been approvable for the post-op indication since June 8.